TWC
CLRB icon

TD Waterhouse Canada’s Cellectar Biosciences CLRB Stock Holding History

TD Waterhouse Canada’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178 Hold
63
– – ﹤0.01% 2299
2026
Q1 		$154 Hold
63
– – ﹤0.01% 2201
2025
Q4 		$181 Buy
+63
New +$233 ﹤0.01% 1944

Other funds holding CLRB

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.65% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

TD Waterhouse Canada's CLRB Position: Q2 2026 in Review

TD Waterhouse Canada held its Cellectar Biosciences (CLRB) position steady in Q2 2026 at 63 shares worth $178. The position accounts for ﹤0.01% of the portfolio, ranked #2299.

TD Waterhouse Canada first reported a position in CLRB in Q4 2025 and has held it in 3 quarters since. The position peaked at $181 in Q4 2025. 29 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • TD Waterhouse Canada held 63 shares of Cellectar Biosciences worth $178 as of Q2 2026.
  • TD Waterhouse Canada left its Cellectar Biosciences share count unchanged in Q2 2026.
  • Cellectar Biosciences made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #2299 holding.
  • TD Waterhouse Canada first reported a position in Cellectar Biosciences in Q4 2025 and has held it in 3 quarters since.
  • TD Waterhouse Canada's Cellectar Biosciences position peaked at $181 in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.